human cnp 53 Search Results


cnp (32-53)  (Bachem)
90
Bachem cnp (32-53)
Cnp (32 53), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cnp+53/us07410962-346-51-63?v=Bachem
Average 90 stars, based on 1 article reviews
cnp (32-53) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human cnp-53  (Asubio Pharma Co)
90
Asubio Pharma Co human cnp-53
Human Cnp 53, supplied by Asubio Pharma Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cnp+53/pmc06532844-25-0-7?v=Asubio+Pharma+Co
Average 90 stars, based on 1 article reviews
human cnp-53 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human cnp peptide (32–53)  (Bachem)
90
Bachem human cnp peptide (32–53)
Human Cnp Peptide (32–53), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cnp+53/pm16602133-33-3-12?v=Bachem
Average 90 stars, based on 1 article reviews
human cnp peptide (32–53) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human cnp 53  (Peptide Institute)
86
Peptide Institute human cnp 53
Quantitative real-time RT-PCR analyses of NPPC ( a ) and NPR2 ( b ) mRNA expression in HPAECs exposed to Hx. mRNA expression of EDN1 ( c ), IL6 ( d ), CCL2 ( e ), and TGFB1 ( f ) in HPAECs transfected with control siRNA or siGC-B under normoxic and Hx conditions, with or <t>without</t> <t>CNP-53</t> treatment. Hx-induced upregulation of these genes was abolished by CNP-53 in control cells, but not in siGC-B-transfected cells. g Knockdown efficiency of GC-B shown as reduced NPR2 mRNA levels in siGC-B–transfected HPAECs compared to scramble controls. ( n = 8 biological replicates, independent culture wells , per group). GAPDH was used as the internal control. Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.
Human Cnp 53, supplied by Peptide Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cnp+53/pmc12996325-337-0-20?v=Peptide+Institute
Average 86 stars, based on 1 article reviews
human cnp 53 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
cnp-53, human  (Biosynth Carbosynth)
N/A
   Buy from Supplier

Image Search Results


Quantitative real-time RT-PCR analyses of NPPC ( a ) and NPR2 ( b ) mRNA expression in HPAECs exposed to Hx. mRNA expression of EDN1 ( c ), IL6 ( d ), CCL2 ( e ), and TGFB1 ( f ) in HPAECs transfected with control siRNA or siGC-B under normoxic and Hx conditions, with or without CNP-53 treatment. Hx-induced upregulation of these genes was abolished by CNP-53 in control cells, but not in siGC-B-transfected cells. g Knockdown efficiency of GC-B shown as reduced NPR2 mRNA levels in siGC-B–transfected HPAECs compared to scramble controls. ( n = 8 biological replicates, independent culture wells , per group). GAPDH was used as the internal control. Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Journal: Nature Communications

Article Title: Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension

doi: 10.1038/s41467-026-70139-2

Figure Lengend Snippet: Quantitative real-time RT-PCR analyses of NPPC ( a ) and NPR2 ( b ) mRNA expression in HPAECs exposed to Hx. mRNA expression of EDN1 ( c ), IL6 ( d ), CCL2 ( e ), and TGFB1 ( f ) in HPAECs transfected with control siRNA or siGC-B under normoxic and Hx conditions, with or without CNP-53 treatment. Hx-induced upregulation of these genes was abolished by CNP-53 in control cells, but not in siGC-B-transfected cells. g Knockdown efficiency of GC-B shown as reduced NPR2 mRNA levels in siGC-B–transfected HPAECs compared to scramble controls. ( n = 8 biological replicates, independent culture wells , per group). GAPDH was used as the internal control. Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Article Snippet: Human CNP-53, a long-acting NPR-B activator that is refractory to NEP and has limited interaction with NPR-C, was purchased from Peptide Institute (No. 4241-s, Ibaraki, Osaka, Japan).

Techniques: Quantitative RT-PCR, Expressing, Transfection, Control, Knockdown

Effect of continuous subcutaneous infusion of CNP-53 (0.2 mg/kg/day) on systemic BP in Tie2-Cre control, GC-B ecKO and GC-B smcKO mice in the MCTp-induced model ( a ; 10-week-old) and Hx-induced model ( b ; 12-week-old) ( n = 3 per group). Effects of CNP-53 infusion on RVSP ( c , e ) and RV/(LV + IVS) ratios ( d , f ) in Tie2-Cre mice under MCTp ( c , d ; 10-week-old) and Hx ( e , f ; 12-week-old) conditions (MCTp model: n = 5 for untreated [MCTp (–)/CNP (–)], n = 5 for MCTp (+)/CNP (–), n = 3 for MCTp (+)/CNP (+); Hx model: n = 5 for normoxia/CNP (–), n = 5 for Hx/CNP (–), n = 3 for Hx/CNP (+)). Effects of CNP-53 infusion on RVSP ( g , i ) and RV/(LV + IVS) ratios ( h , j ) in GC-B ecKO and GC-B smcKO mice under MCTp ( g , h ; 10-week-old) and Hx ( i , j ; 12-week-old) conditions (MCTp model: n = 5 for MCTp (–)/CNP (–), n = 5 for MCTp (+)/CNP (–), n = 3 for MCTp (+)/CNP (+); Hx model: n = 5 for normoxia/CNP (–), n = 5 for Hx/CNP (–), n = 3 for Hx/CNP (+)). Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Journal: Nature Communications

Article Title: Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension

doi: 10.1038/s41467-026-70139-2

Figure Lengend Snippet: Effect of continuous subcutaneous infusion of CNP-53 (0.2 mg/kg/day) on systemic BP in Tie2-Cre control, GC-B ecKO and GC-B smcKO mice in the MCTp-induced model ( a ; 10-week-old) and Hx-induced model ( b ; 12-week-old) ( n = 3 per group). Effects of CNP-53 infusion on RVSP ( c , e ) and RV/(LV + IVS) ratios ( d , f ) in Tie2-Cre mice under MCTp ( c , d ; 10-week-old) and Hx ( e , f ; 12-week-old) conditions (MCTp model: n = 5 for untreated [MCTp (–)/CNP (–)], n = 5 for MCTp (+)/CNP (–), n = 3 for MCTp (+)/CNP (+); Hx model: n = 5 for normoxia/CNP (–), n = 5 for Hx/CNP (–), n = 3 for Hx/CNP (+)). Effects of CNP-53 infusion on RVSP ( g , i ) and RV/(LV + IVS) ratios ( h , j ) in GC-B ecKO and GC-B smcKO mice under MCTp ( g , h ; 10-week-old) and Hx ( i , j ; 12-week-old) conditions (MCTp model: n = 5 for MCTp (–)/CNP (–), n = 5 for MCTp (+)/CNP (–), n = 3 for MCTp (+)/CNP (+); Hx model: n = 5 for normoxia/CNP (–), n = 5 for Hx/CNP (–), n = 3 for Hx/CNP (+)). Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Article Snippet: Human CNP-53, a long-acting NPR-B activator that is refractory to NEP and has limited interaction with NPR-C, was purchased from Peptide Institute (No. 4241-s, Ibaraki, Osaka, Japan).

Techniques: Control

SuHx rat model. RVSP ( a ), RV/(LV + IVS) ratios ( b ) and BP ( c ) in SuHx rats treated with vehicle or CNP-53 (0.2 mg/kg/day) ( n = 5 per group). d – g SuHx mouse model (wild-type). RVSP ( d ) and RV/(LV + IVS) ratios ( e ) in SuHx mice treated with vehicle, CNP-53 (0.2 mg/kg/day), macitentan (20 mg/kg/day) or the combination of macitentan and CNP-53. RVSP ( f ) and RV/(LV + IVS) ratios ( g ) in SuHx mice treated with vehicle, CNP-53, sotatercept (10 mg/kg twice weekly) or the combination of sotatercept and CNP-53 (controls and SuHx+vehicle groups, n = 5 each; macitentan group, n = 6; sotatercept group, n = 7). h – k SuHx mouse model (CNP ecKO). RVSP ( h ) and RV/(LV + IVS) ratios ( i ) in SuHx mice treated with vehicle, CNP-53 (0.2 mg/kg/day), macitentan (20 mg/kg/day) or the combination of macitentan and CNP-53. RVSP ( j ) and RV/(LV + IVS) ratios ( k ) in SuHx mice treated with vehicle, CNP-53, sotatercept (10 mg/kg twice weekly) or the combination of sotatercept and CNP-53 (controls and SuHx+vehicle groups, n = 5 each; macitentan group, n = 5; sotatercept group, n = 6). Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Journal: Nature Communications

Article Title: Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension

doi: 10.1038/s41467-026-70139-2

Figure Lengend Snippet: SuHx rat model. RVSP ( a ), RV/(LV + IVS) ratios ( b ) and BP ( c ) in SuHx rats treated with vehicle or CNP-53 (0.2 mg/kg/day) ( n = 5 per group). d – g SuHx mouse model (wild-type). RVSP ( d ) and RV/(LV + IVS) ratios ( e ) in SuHx mice treated with vehicle, CNP-53 (0.2 mg/kg/day), macitentan (20 mg/kg/day) or the combination of macitentan and CNP-53. RVSP ( f ) and RV/(LV + IVS) ratios ( g ) in SuHx mice treated with vehicle, CNP-53, sotatercept (10 mg/kg twice weekly) or the combination of sotatercept and CNP-53 (controls and SuHx+vehicle groups, n = 5 each; macitentan group, n = 6; sotatercept group, n = 7). h – k SuHx mouse model (CNP ecKO). RVSP ( h ) and RV/(LV + IVS) ratios ( i ) in SuHx mice treated with vehicle, CNP-53 (0.2 mg/kg/day), macitentan (20 mg/kg/day) or the combination of macitentan and CNP-53. RVSP ( j ) and RV/(LV + IVS) ratios ( k ) in SuHx mice treated with vehicle, CNP-53, sotatercept (10 mg/kg twice weekly) or the combination of sotatercept and CNP-53 (controls and SuHx+vehicle groups, n = 5 each; macitentan group, n = 5; sotatercept group, n = 6). Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Article Snippet: Human CNP-53, a long-acting NPR-B activator that is refractory to NEP and has limited interaction with NPR-C, was purchased from Peptide Institute (No. 4241-s, Ibaraki, Osaka, Japan).

Techniques: